



## PRESS RELEASE

Published 20-05-2019

### Asarina Pharma AB (publ) Interim Report, Q1 2019 released

(Stockholm May 20, 2019) **Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management - leading to a solid cash position at the end of the First Quarter.”**

#### Financial Highlights

The company maintained a strict management of its costs. The total cash position at the end of the Quarter was SEK 128.9 million.

#### The Quarter in Brief

**PMDD:** Our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD) made good progress, with a drop-out rate of less than 15% compared to more than 30% average in other late stage clinical PMDD studies. We expect topline results in early 2020.

**MENSTRUAL MIGRAINE:** Our Phase IIa proof-of-concept study in Menstrual Migraine (MM) is on schedule to start enrolment of patients in July. A CTA has been submitted in Sweden and CTAs will be submitted in Denmark and Finland shortly.

**AUTOINJECTORS:** We are focusing on identifying the best possible autoinjector to administer Sepranolone in future studies and expect to select the final autoinjector for Phase III studies and commercialization in June.

**TOURETTE SYNDROME:** We published exciting data on Tourette syndrome in March. The data indicate that Sepranolone reduces tics in an animal model of Tourette syndrome on a par with Haldol, the current first-line treatment, without inducing any motor side effects.

For further information see the attached, plus please visit [www.asarinapharma.com](http://www.asarinapharma.com)

#### For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: [peter.nordkild@asarinapharma.com](mailto:peter.nordkild@asarinapharma.com)

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Phone: +45 5132 3698

E-mail: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

**Certified Adviser**

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

**About Asarina Pharma**

We are a Swedish biotech company developing Sepranolone, the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSAs (GABA<sub>A</sub> Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women's Health company.

***The information above was provided by Asarina Pharma AB (publ) through the above contact person, for publication on May 20, 08.00, 2019.***